Summary
Fingolimod is the first oral disease therapy approved for relapsing-remitting multiple sclerosis (MS). Patients can be switched directly from interferon-β or glatiramer acetate to fingolimod without a washout period. Fingolimod's potent efficacy, oral route of administration, and generally good safety and tolerability make it appealing to patients and clinicians. However, several adverse effects have already been identified, overall experience with its use is limited compared to other agents, and its novel and complex mechanism of action make predicting adverse effects challenging. Fingolimod's place in the MS treatment algorithm is evolving. We anticipate that once centers have solved the logistical issues associated with fingolimod initiation and if the experience in clinical practice parallels the efficacy, safety, and tolerability demonstrated in the phase 3 trials, fingolimod's routine use will increase.

Fingolimod (FTY720, Gilenya, Novartis) is the first oral disease therapy approved for relapsing-remitting multiple sclerosis (RRMS). This review summarizes its mechanism of action, clinical trial results for efficacy and safety, and clinical use.

Mechanism of action
The active form of fingolimod, fingolimod-phosphate, is a sphingosine 1-phosphate receptor (S1PR) modulator that renders naive and central memory T-cells and B-cells insensitive to the S1P chemotactic signal necessary for egress from lymph nodes. The resultant interference with lymphocyte recirculation is thought to reduce trafficking of pathogenic lymphocytes into the CNS in multiple sclerosis (MS).¹ Peripheral lymphocyte counts decrease to 20%–30% of baseline within the first several weeks of fingolimod administration and recover in most patients 4–8 weeks after discontinuation. T cells are affected more than B cells, with a greater drop in CD4⁺ than CD8⁺ T cells. In addition,
Fingolimod penetrates the CNS, and interaction with S1PRs on neural cells may also contribute to its mechanism of action through neuroprotective or repair-promoting effects.¹

**Efficacy results in clinical trials**
Fingolimod received regulatory approval following 2 phase 3 clinical trials that evaluated fingolimod doses of 0.5 mg and 1.25 mg in RRMS. The FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study² was a 24-month placebo-controlled study of 1,272 patients. The Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS) study³ was a 12-month study of 1,292 patients comparing fingolimod to IM interferon β-1a (IFNβ-1a). Both studies demonstrated reduction in annualized relapse rate (the primary endpoint): 0.16 – 0.18 in the fingolimod groups vs 0.40 in the placebo group in FREEDOMS (p < 0.001); 0.16 – 0.20 in fingolimod groups vs 0.33 in the IFNβ-1a group in TRANSFORMS (p < 0.001). Fingolimod slowed disability progression relative to placebo in FREEDOMS and reduced MRI lesion activity and brain atrophy progression in both studies. Efficacy was similar for 0.5 mg and 1.25 mg fingolimod doses in both studies, while adverse events (AEs) were more common with 1.25 mg. The better efficacy–safety relationship led to submission of 0.5 mg for regulatory approval.

**Adverse events**
Known pharmacodynamic effects of fingolimod mediated by S1PRs explain many of its AEs. The mechanisms of others remain uncertain. The risk of any AE in the phase 3 trials was similar across treatment groups and ranged from 86% to 94%.²,³ In FREEDOMS, the study drug discontinuation rates for fingolimod 0.5 mg (7.5%) and placebo (7.7%) were similar, and less than for fingolimod 1.25 mg (14.2%). In TRANSFORMS, the rates of AEs leading to study drug discontinuation were 10% for fingolimod 1.25 mg, 5.6% for fingolimod 0.5 mg, and 3.7% for IFNβ-1a. AEs associated with fingolimod included laboratory abnormalities (lymphopenia or liver enzyme elevations), first-dose bradycardia or slowed atrioventricular (AV) conduction, hypertension, macular edema, possible increased infection risk, cough, dyspnea, back pain, headache, influenza, and diarrhea.

The total number of patients with infections with fingolimod was similar to the comparison groups, aside from mildly increased lower respiratory tract infections. Serious and severe infections were not increased. However, 2 of 3 deaths in patients treated with fingolimod 1.25 mg were related to herpesvirus infections. There was no correlation between lymphocyte count and incidence, type, or severity of infections.¹ Because lymphocytes are not depleted but are redistributed from blood to secondary lymphoid organs and their overall function is preserved, the utility of monitoring peripheral blood lymphocyte counts, including lymphocyte subsets, to predict risk of infection is unclear at present.

**Use in practice**
Beginning in September 2010, the 0.5 mg dose of fingolimod was approved in multiple countries to reduce relapses and delay accumulation of physical disability in relapsing forms of
Fingolimod is an appropriate option for patients with RRMS with intolerable side effects on IFNβ or glatiramer acetate (GA) or an inadequate therapeutic response (recognizing that precise criteria for this are lacking), particularly in patients who are seropositive for JC virus and, thus, at risk for progressive multifocal leukoencephalopathy with natalizumab. The utility of fingolimod relative to natalizumab in JC virus–seronegative patients remains to be defined. Although fingolimod has been approved in the United States as a first-line agent, at present we tend to recommend IFNβ or GA to treatment-naive patients, largely because of the greater experience with their use. Similarly, we do not routinely advise patients with effective disease control on IFNβ or GA and good tolerability to switch to fingolimod. However, we anticipate that if broad use in clinical practice and postmarketing studies confirm good safety, our use of fingolimod as a first-line agent will increase.

Practical aspects related to use of fingolimod are summarized in the table. Pretreatment testing includes complete blood count (CBC) and hepatic panel, pregnancy test in woman of childbearing potential, EKG to rule out bradycardia or an AV conduction abnormality, ophthalmic examination or optical coherence tomography to rule out macular edema, and varicella zoster serology for patients without a clearcut history of chicken pox. Varicella zoster vaccination should be considered prior to fingolimod initiation in patients without prior exposure. An eye examination should be repeated 3–4 months after starting fingolimod treatment. The package insert does not recommend a specific frequency for CBC and hepatic panel monitoring. In general, we repeat a CBC and hepatic panel every 6 months after starting fingolimod, but given the rapid drop in lymphocyte count, including to a level below 0.2 in a small proportion of patients, some practitioners monitor CBC earlier or more frequently.

Initial binding of fingolimod-phosphate to S1PRs on atrial myocytes leads to transient bradycardia and rare AV conduction slowing. With receptor desensitization, these effects resolve despite continued treatment. United States Food and Drug Administration guidelines recommend that patients be observed for 6 hours following the first fingolimod dose, which creates logistical issues. Some MS centers such as ours have utilized group visits to provide nursing oversight and monitor vital signs after the first dose, and intervene if needed for symptomatic bradycardia or AV conduction block.

Fingolimod should be used as monotherapy. There are no published data concerning safety and efficacy of fingolimod as combination therapy in MS or concerning use in progressive MS.
The approved dose is 0.5 mg by mouth once daily. Steady state levels are reached after 4–8 weeks. Absorption and elimination are not affected by food, ethnicity, gender, or mild to moderate hepatic or renal impairment. Fingolimod does not interact significantly with corticosteroids or drugs commonly used to treat MS symptoms. Fingolimod should be combined with caution with Class la or III anti-arrhythmic drugs, β-blockers, calcium channel blockers, and ketoconazole. Fingolimod is approved as monotherapy; no data exist concerning the safety or utility of combining it with other immunomodulatory or immunosuppressive medications. Concomitant use with immunosuppressive medications would be expected to increase the risk of infection.

Patients can be switched directly from interferon β or GA to fingolimod. Very few data exist concerning switching from other MS disease therapies.

Patients with pre-existing liver disease are at increased risk of liver abnormalities with fingolimod therapy. Transaminase and bilirubin levels should be checked prior to treatment and periodically on treatment, particularly in patients with symptoms suggestive of hepatic dysfunction. Discontinue fingolimod in patients who develop significant liver injury. Use fingolimod with caution in patients with severe hepatic impairment, which increases exposure.

Patients receiving Class la (e.g., quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) anti-arrhythmic drugs, β-blockers, and calcium channel blockers; with a low baseline heart rate; or with a history of syncope, sick sinus syndrome, second-degree or higher AV conduction block, ischemic heart disease, or congestive heart failure may be at increased risk of symptomatic bradycardia or AV conduction abnormalities. ECG should be performed prior to treatment. Patient should be monitored clinically for 6 hours after the first dose. Symptomatic bradycardia or AV conduction slowing can be treated with isoproterenol or atropine. If fingolimod is discontinued for >2 weeks, effects on heart rate and AV conduction may recur on reintroduction, so the same precautions apply.

Obtain ophthalmologic examination or OCT prior to fingolimod therapy, 3–4 months after treatment initiation, and for reports of visual disturbance. Diabetes mellitus and uveitis may increase the risk of macular edema. The risks of continued fingolimod therapy in patients who develop macular edema or of rechallenge are unknown.

Blood pressure should be monitored during therapy and treated as necessary.

Routine pulmonary testing currently is not recommended prior to or during fingolimod therapy, but should be considered if clinically indicated.

Obtain CBC prior to initiation of therapy and periodically on treatment. Therapy should not be started in patients with acute or chronic infections. Patients without a history of chicken pox or VZV vaccination should undergo serologic testing for VZV antibodies. VZV seronegative patients should receive VZV vaccination, and therapy should be postponed for 1 month. Monitor patients for symptoms/signs of infection during therapy and for 2 months after discontinuation. Live attenuated vaccines should be avoided during fingolimod therapy and for 2 months after discontinuation.

No special monitoring for cancer currently is recommended.

Fingolimod is pregnancy Category C.

Obtain pregnancy test prior to therapy and for suspected pregnancy. Women of childbearing potential should practice effective contraception during and for 2 months after fingolimod therapy.

No data exist concerning use of fingolimod in children or adolescents.

Experience with fingolimod in patients >55 years of age is limited.

Abbreviations: AV = atrioventricular; CBC = complete blood count; ECG = electrocardiogram; GA = glatiramer acetate; MS = multiple sclerosis; OCT = optical coherence tomography; VZV = varicella zoster virus.
or neuromyelitis optica. A phase 3 trial in primary progressive MS is ongoing. The safety and efficacy of fingolimod in pediatric and elderly patients are not established. Fingolimod should not be used during pregnancy. Women of childbearing potential should use effective contraception during and for 2 months after fingolimod therapy.

REFERENCES

DISCLOSURES
Dr. Hyland reports no disclosures. Dr. Cohen has received honoraria for consulting or speaking from Biogen Idec, Elan Corporation, Eli Lilly and Company, Novartis, Teva Pharmaceutical Industries Ltd. and Vaccinex, Inc.; receives publishing royalties for Multiple Sclerosis Therapeutics (Cambridge University Press, 2011); and receives research support from Biogen Idec, Novartis, Genzyme Corporation, Teva Pharmaceutical Industries Ltd., and the Immune Tolerance Network.
Fingolimod
Megan H. Hyland and Jeffrey A. Cohen
Neurol Clin Pract 2011;1:61-65
DOI 10.1212/CPJ.0b013e31823c51dd

This information is current as of December 1, 2011

Updated Information & Services
including high resolution figures, can be found at:
http://cp.neurology.org/content/1/1/61.full.html

References
This article cites 4 articles, 0 of which you can access for free at:
http://cp.neurology.org/content/1/1/61.full.html##ref-list-1

Citations
This article has been cited by 3 HighWire-hosted articles:
http://cp.neurology.org/content/1/1/61.full.html##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Clinical Neurology
http://cp.neurology.org/cgi/collection/all_clinical_neurology
All Demyelinating disease (CNS)
http://cp.neurology.org/cgi/collection/all_demyelinating_disease_cns
Decision analysis
http://cp.neurology.org/cgi/collection/decision_analysis
Multiple sclerosis
http://cp.neurology.org/cgi/collection/multiple_sclerosis
Patient safety
http://cp.neurology.org/cgi/collection/patient__safety

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://cp.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright Copyright © 2011 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.